BlackRock
BCLI

BlackRock’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

BlackRock’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,172
Closed -$28.2K – 5462
2025
Q2 		$28.2K Hold
25,172
– – ﹤0.01% 5088
2025
Q1 		$31.7K Hold
25,172
– – ﹤0.01% 5010
2024
Q4 		$57.1K Sell
25,172
-2
-0% -$4 ﹤0.01% 4912
2024
Q3 		$87K Sell
25,174
-587
-2% -$2.77K ﹤0.01% 4697
2024
Q2 		$131K Sell
25,761
-6,860
-21% -$51.4K ﹤0.01% 4634
2024
Q1 		$276K Buy
32,621
+1,531
+5% +$8.42K ﹤0.01% 4523
2023
Q4 		$127K Sell
31,090
-71
-0.2% -$213 ﹤0.01% 4750
2023
Q3 		$93.5K Sell
31,161
-1,203
-4% -$27.4K ﹤0.01% 4863
2023
Q2 		$1M Buy
32,364
+758
+2% +$31.4K ﹤0.01% 4296
2023
Q1 		$1.56M Buy
31,606
+155
+0.5% +$4.5K ﹤0.01% 4156
2022
Q4 		$774K Buy
31,451
+230
+0.7% +$8.6K ﹤0.01% 4496
2022
Q3 		$2.07M Sell
31,221
-361
-1% -$18.1K ﹤0.01% 4178
2022
Q2 		$1.31M Sell
31,582
-52
-0.2% -$2.34K ﹤0.01% 4426
2022
Q1 		$1.59M Buy
31,634
+136
+0.4% +$6.68K ﹤0.01% 4487
2021
Q4 		$1.89M Buy
31,498
+234
+0.7% +$11.5K ﹤0.01% 4426
2021
Q3 		$1.55M Sell
31,264
-359
-1% -$18.9K ﹤0.01% 4424
2021
Q2 		$1.8M Sell
31,623
-98,593
-76% -$5.27M ﹤0.01% 4321
2021
Q1 		$7.48M Buy
130,216
+2,193
+2% +$166K ﹤0.01% 3741
2020
Q4 		$8.69M Buy
128,023
+3,164
+3% +$431K ﹤0.01% 3438
2020
Q3 		$31.7M Buy
124,859
+984
+0.8% +$202K ﹤0.01% 2581
2020
Q2 		$20.8M Buy
123,875
+98,275
+384% +$10.6M ﹤0.01% 2774
2020
Q1 		$1.78M Buy
25,600
+14,564
+132% +$1.14M ﹤0.01% 3688
2019
Q4 		$709K Buy
11,036
+2,070
+23% +$120K ﹤0.01% 4093
2019
Q3 		$525K Buy
8,966
+281
+3% +$16.6K ﹤0.01% 4157
2019
Q2 		$514K Buy
8,685
+2,679
+45% +$156K ﹤0.01% 4187
2019
Q1 		$392K Buy
6,006
+320
+6% +$18.2K ﹤0.01% 4132
2018
Q4 		$303K Buy
5,686
+15
+0.3% +$739 ﹤0.01% 4156
2018
Q3 		$325K Buy
5,671
+158
+3% +$9.55K ﹤0.01% 4223
2018
Q2 		$323K Buy
5,513
+235
+4% +$13.8K ﹤0.01% 4205
2018
Q1 		$249K Sell
5,278
-312
-6% -$15.7K ﹤0.01% 4163
2017
Q4 		$328K Buy
5,590
+315
+6% +$18.8K ﹤0.01% 4117
2017
Q3 		$326K Sell
5,275
-109
-2% -$7.05K ﹤0.01% 4133
2017
Q2 		$335K Buy
5,384
+246
+5% +$15.2K ﹤0.01% 4119
2017
Q1 		$327K Buy
+5,138
New +$267K ﹤0.01% 4084

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

BlackRock's BCLI Position: Q3 2025 in Review

BlackRock sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 25,172 shares — an estimated $28.2K sold.

BlackRock first reported a position in BCLI in Q1 2017 and held it in 34 quarters. The position peaked at $31.7M in Q3 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • BlackRock reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • BlackRock sold 25,172 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $28.2K.
  • BlackRock first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2017 and held it in 34 quarters.
  • BlackRock's BRAINSTORM CELL THERAPUTC position peaked at $31.7M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.